Fluconazole tolerance in clinical isolates of Cryptococcus neoformans | Zendy

Venkateswarlu Kanamarlapudi | Zendy; Maureen B. Taylor | Zendy; N. J. Manning | Zendy; Michael G. Rinaldi | Zendy; Steven L. Kelly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans

Author(s) -

Venkateswarlu Kanamarlapudi,

Maureen B. Taylor,

N. J. Manning,

Michael G. Rinaldi,

Steven L. Kelly

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.4.748

Subject(s) - fluconazole , cryptococcus neoformans , microbiology and biotechnology , ergosterol , biology , amphotericin b , fungi imperfecti , sterol , mycosis , drug resistance , cryptococcus , antifungal , immunology , biochemistry , cholesterol

Eleven isolates of Cryptococcus neoformans were investigated to determine the biochemical basis of their tolerance to fluconazole. The MICs of fluconazole for three isolates with low-level resistance were 3- to 6-fold higher than those for sensitive isolates, while the MICs for four isolates with high-level resistance were 100- to 200-fold higher than those for sensitive isolates. The level of ergosterol present in the isolates varied, and those which had relatively low levels of ergosterol were resistant to amphotericin B. Changes in the affinity of the target enzyme (sterol 14alpha-demethylase) and decreases in the cellular content of fluconazole seemed to be responsible for the resistance in isolates with low-level and high-level resistance, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research